RUNX1 and acute lymphoblastic leukemia: To allow for the identification of kinase-activating genetic alterations potentially targetable by TKIs, several other translocations (PDGFRB, ABL1, ABL2, and CSF1R, as well CRLF2, IGH, EPOR, and NTRK3) are analyzed in all BCP-ALL patients with positive MRD results on day 33 from the beginning of therapy (TP1) and without positive results for ETV6-RUNX1, rearranged TCF3, and hypodiploidy [10].